Innovation Pharmaceuticals (OTCMKTS: IPIX) Completes Enrolment in Phase 2 Brilacidin Study in Hospitalized COVID-19 Patients

July 23, 2021

Innovation Pharmaceuticals (OTCMKTS: IPIX) has announced that it has met complete patient registration for its double-blind, randomized placebo-controlled second phase clinical study of Brilacidin in treating hospitalized patients with moderate to severe COVID-19. The company is developing the drug for COVID-19 treatment under the FDA Fast Track Designation. Innovation Pharmaceuticals enrolled 120 patients in the Brilacidin study  A total of 120 dosed participants were recruited across several sites for the…

Read More >>